# Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection

> **NCT03760484** · PHASE2 · TERMINATED · sponsor: **University of Alberta** · enrollment: 4 (actual)

## Conditions studied

- Clostridium Difficile

## Interventions

- **DRUG:** Fidaxomicin 200 mg
- **BIOLOGICAL:** fecal microbiota transplantation (FMT)

## Key facts

- **NCT ID:** NCT03760484
- **Lead sponsor:** University of Alberta
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-01-21
- **Primary completion:** 2020-03-10
- **Final completion:** 2020-03-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Difficulty enrolling participants/COVID pandemic/lack of continued in-kind support from product manufacturer.
- **Last updated:** 2022-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03760484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03760484, "Fecal Microbiota Transplant (FMT) Plus Fidaxomicin for Severe or Fulminant Clostridium Difficile Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03760484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*